Starting
Initialising…
0%
PTEN
Final classification
VUS
PTEN c.431A>C · p.Lys144Thr
PTEN

NM_000314.8:c.431A>C (NP_000305.3:p.Lys144Thr) is a missense variant in exon 5 of PTEN.

Gene
PTEN
Transcript
NM_000314.8
HGVS · transcript:coding
NM_000314.8:c.431A>C
Consequence
N/A
GRCh38
chr10:87933190 A>C
GRCh37
chr10:89692947 A>C
Basis Richards et.al., 2015 - Combining rules v3.2.0 criteria-combination framework was evaluated deterministically with applied criteria: PM2 supporting, PP2 supporting; no rule matched the adjudicated criteria.
Richards et.al., 2015 - Combining rules v3.2.0 criteria-combination framework was evaluated deterministically with applied criteria: PM2 supporting, PP2 supporting; no rule matched the adjudicated criteria.
Classification rationale
PM2PP2 VUS
PTEN c.431A>C

NM_000314.8:c.431A>C (NP_000305.3:p.Lys144Thr) is a missense variant in exon 5 of PTEN. This variant is absent from gnomAD v2.1 and v4.1 (PM2_Supporting per VCEP).1 PTEN has a low rate of benign missense variation and missense variants are a common disease mechanism (PP2_Supporting per VCEP).2 Functional data from Mighell et al. 2018 saturation mutagenesis assay shows a cumulative fitness score of -0.15 for K144T, indicating mild functional impairment that does not meet PS3 or BS3 thresholds.3 REVEL score of 0.691 does not exceed the VCEP PP3 threshold of >0.7; SpliceAI predicts no splice impact.4 The variant lies outside the PTEN catalytic motifs (residues 90-94, 123-130, 166-168); PM1 is not met.5 This variant has been reported in ClinVar as Uncertain Significance (1 submitter, VCV2687516). It has been observed somatically in 3 cancer samples (COSMIC COSV64295211).6 No case-level proband data, de novo observations, co-segregation data, or same-residue pathogenic comparator variants were identified. With 2 supporting-level pathogenic criteria (PM2_Supporting, PP2_Supporting) and no benign criteria met, the variant does not reach the combination threshold for Likely Pathogenic or Pathogenic under the PTEN VCEP v3.2.0 rules. The variant remains a Variant of Uncertain Significance.7

PM2 + PP2 VUS
3 vcep_mmc2
4 revelspliceai ↗
7 cspec ↗final_classification_framework
Gene diagram · NM_000314.8 · variants mapped to exon structure
PTEN NM_000314.8
Fetching transcript structure from UCSC…
Applied criteria · 2 met · select any tile
Met
Not met
Not assessed
N/A
Strength very strong supporting
Pathogenic evidence
PVS
PS
PM
PP
Benign evidence
BA
BS
BP
Rationale
Select a criterion.
Sources
Evidence used
    Gaps remaining
      Rule
      Research & evidence
      Population frequency
      gnomAD v4.1 screenshot
      gnomAD v4.1
      gnomAD v2.1 screenshot
      gnomAD v2.1
      Population frequency
      Absent from gnomAD v4.1.
      Absent from gnomAD v2.1.
      This variant is absent from gnomAD-Canada.
      ClinVar screenshot
      ClinVar
      This variant has been reported in ClinVar as Uncertain significance (1 clinical laboratory). (ClinVarID = 2687516)
      SpliceAI screenshot
      In silico
      SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.691. BayesDel score = 0.0587913.
      Functional / OncoKB screenshot
      Functional Unknown Oncogenic Effect
      OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. PTEN, a lipid and protein phosphatase, is one of the most frequently mutated genes in cancer.
      OncoKB ↗
      COSMIC screenshot
      COSMIC
      Cancer hotspots screenshot
      Cancer hotspots
      Somatic evidence Not in COSMIC / hotspots
      COSMIC
      This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV64295211, n = 3 times).
      Hotspots
      This variant does not lie in a statistically significant hotspot.
      Literature · 3 PMIDs triaged · 3 high-priority
      3papers screened
      Papers triaged by theme: functional/splicing/segregation/case_observation. high_priority_papers include abstract snippets. Use these to support PS3/BS3/PS4/PP1/PP3/PP5.
      25394175 ↗ case observation
      A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.
      The practice guidelines of the American College of Medical Genetics and Genomics (ACMG) and the National Society of Genetic Counselors (NSGC) are developed by members of the ACMG and NSGC to assist medical geneticists, genetic counselors, and other health-care providers in making decisions about appropriate management of genetic concerns, including access to and/or delivery of services. Each pract
      PP5PS4
      31829902 ↗ case observation
      Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.
      This guideline provides recommendations for available tissue-based prostate cancer biomarkers geared toward patient selection for active surveillance, identification of clinically significant disease, choice of postprostatectomy adjuvant versus salvage radiotherapy, and to address emerging questions such as the relative value of tissue biomarkers compared with magnetic resonance imaging. An ASCO m
      PP5PS4
      35924163 ↗ case observation
      Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
      In recent years, indications for genetic testing in prostate cancer (PC) have expanded from patients with a family history of prostate and/or related cancers to those with advanced castration-resistant disease, and even to early PC patients for determination of the appropriateness of active surveillance. The current consensus aims to provide guidance to urologists, oncologists and pathologists wor
      PP5PS4
      Sources & reference links
      8Sources
      CSpec VCEP
      ClinVar
      gnomAD v2.1
      gnomAD v4.1
      SpliceAI
      OncoKB
      COSMIC
      Cancer hotspots